Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000224869 is annotated as a pseudogene, specifically related by homology to the gene encoding proteins with fibronectin type III domains (FN3), which are structural motifs found in a wide range of cell-adhesion molecules and other extracellular proteins[3]. Pseudogenes are generally nonfunctional DNA sequences that resemble protein-coding genes but contain disabling mutations (such as frameshifts or premature stop codons) that prevent them from producing a functional protein[2][4]. Pseudogenes are not considered therapeutic targets because they do not encode active proteins and typically have no direct biological function or relevance for drug discovery, except in rare cases where their transcripts have regulatory functions as noncoding RNAs[6]. This particular pseudogene does not encode any known receptor, enzyme, transporter, or other canonical drug target class. The presence of "fibronectin type III" in the name is due to its homology with functional domains found in adhesion proteins, but this pseudogene itself does not participate in cellular adhesion or signaling. Note on accuracy: - The label "pseudogene similar to part of fibronectin type III domain containing 3A" covers a nonfunctional genomic locus, not an active molecular entity. - Therefore, this entity is not a drug target, is not therapeutically relevant, and is not a functional protein[2][4]. - The use of "pseudogene" confirms that druggability, molecular classification, biological function, and disease role fields are inapplicable or null.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pseudogene similar to part of fibronectin type III domain containing 3A (ENSG00000224869).